header-4.jpg
About Us

Pamela Russell

Pamela Russell

Positions

  • Emeritus Professor, Head of Biomedical Imaging and Prostate Cancer Models, APCRC-Q
  • Emeritus Professor, IHBI, QUT
  • Adjunct Professor, Centre for Advanced Imaging, University of Queensland.

Contact Details

Phone
+61 7 3443 7240

Qualifications

  • DipEd, Canberra University, Australia, 1979
  • PhD, Autoimmunity, Sir Gustav Nossal, Walter & Eliza Hall Institute of Medical Research, Melbourne, 1968
  • MSc, Autoimmunity, Sir Macfarlane Burnet, Walter & Eliza Hall Institute of Medical Research, Melbourne, 1965
  • BSc, Science (Biochemistry/Microbiology) University of Melbourne, Australia, 1963

Biography

Emeritus Professor Russell, AM (PhD, Dip Ed) has built an international reputation for her work in urological cancers - in particular bladder and prostate cancers. In 2003, she was awarded Membership of the Order of Australia (AM) for her research on bladder and prostate cancer and, in 2015, she was made a fellow of the Australian Academy of Health and Medical Sciences, Limited.

Prof Russell has extensive expertise in establishing cell lines and rare xenografts from primary human tumours and generating urological cancer models, and collaborates widely, within Australia and overseas in USA and Europe. Her recent research focus has been on developing new methods for prostate specific-membrane antigen (PSMA) targeted imaging using 19F-MRI, and studying new biomarkers in exosomes, which may indicate/predict the response of CRPC to chemotherapy.

Nationally, she helped to initiate the Australian Genitourinary Oncology Group and the Prostate Cancer Foundation of Australia (PCFA) (of which she is a life member). From 2007 to 2010 Prof Russell served as an inaugural Director/Secretary of the Australasian Urological and Prostate Cancer Clinical Trials Group (ANZUP). She is also an Australian editor for Urological Research and a member of Movember’s Global Scientific Committee.

In 2006 she received a prize for outstanding research alumnus of Sydney’s Kolling Institute of Medical Research, was made a life member of the Australasian Gene Therapy Society in 2009, and in 2010, PCFA’s Prostate Cancer Researcher of the Year in Australia. She has also served on Movember’s Global Action Plan Scientific Committee (2010-14) and Research Advisory Committees.

She was Professor of Medicine, University of New South Wales (UNSW) and Director of the Oncology Research Centre at the UNSW School of Medicine at Prince of Wales Hospital, Sydney from 1992-2008.

Read More ▼

After training in immunology at the Walter & Eliza Hall Institute of Medical Research in Melbourne with Sir Macfarlane Burnet and Sir Gustav Nossal, she changed her research focus to cancer in 1984, and with Dr Derek Raghavan, set up the Urological Cancer Research Unit at Sydney University.

She has procured >$35M in grants, has published >200 peer reviewed articles, as well as several reviews and book chapters, edited one book and co-authored six patents. She is currently funded by the NHMRC and Movember GAP programs.

Prof Russell has been on peer review committees for the National Health and Medical Research Committee (NHMRC), Cancer Council Australia, Cure Cancer Australia, and regularly reviews papers from international journals. She has delivered presentations or chaired sessions at numerous international prostate cancer meetings.

She has trained 13 Honours students, 7 BSc (Med) students, 3 Masters’ students, 14 PhD and 1 MD student and 31 post-doctoral fellows.

Awards and grants

Awards

2015 Fellow of the Australian Academy of Health and Medical Science, Limited
2010 Inaugural Prostate Cancer Foundation of Australia Prize and Lecture for Outstanding Excellence
2010 Prostate Cancer Foundation of Australia's Researcher of the year
2009 Made Life Member, Australasian Gene Therapy Society
2009 Alban Gee Prize for best poster presentation at USANZ
2007 Member of the year, listed in Madison's Who's Who
2006 Made Honorary Life Member, Prostate Cancer Foundation of Australia
2006 Awarded prize for outstanding alumni of Kolling Institute of Medical Research (75th Jubilee)
2005 Listed in Marquis Who's Who in Medicine and Healthcare, USA
2003-2005 Listed in Who's Who, Australia
2003 Platinum Nomination for the CSIRO Chairman's medal.  Gene Therapy: A new approach for treating prostate cancer
2003 Order of Australia (AM) for outstanding contributions to prostate and bladder cancer research
1962 Dunlop Rubber prize for Biochemistry
1960 Commonwealth Scholarship


Grants

 

2017-2018

Translational Research Institute (TRI) Spore Grant

$80,000

MicroRNA replacement therapy for indolent and aggressive prostate cancer.

Batri J, Russell PJ, Vela I, Cristina A

2016-2018

National Health and Medical Research Council (NHMRC)

Category 1

APP108043

$633,757

Immunopolymeric drugs for prostate cancer therapy

Thurecht K, Russell PJ, Mahler S, Boyd A, Howard C (AIs: Thompson L, Heathcote P, Straw R).

2016-2018

NHMRC

Category 1

APP 108043

$541,000

The Microniche: A novel in-vitro and in-vivo prostate cancer model system

Doran MR, Vela I, Tse B, Russell PJ (AIs Pettit A, Wang C, Clements JA).

2015-2017

Australian Research Council (ARC) Linkage

 LP150100703

$360,000

Next generation hybrid nanomaterials: investigating anti-PET as a component in bispecific antibodies as a novel biomolecule couple technology

Thurecht KJ, Mahler S, Russell PJ, Walsh D, Campbell.

2015-2017

Prostate Cancer Foundation of Australia (PCFA) / Movember Foundation

     $3,250,000

 

Movember Revolutionary Team Award 3: Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer.

Butler L,Collaborators: Tilley W, Hoy A, Wittert G, Nelson CC, Scott A, Swinnen J, Clayton A,Weickhardt A, Davis I, Power C, Bianco-Miotto T, Russell PJ (AI), Brooks D, Sutherland P, Parnis F

2015-2017

NHMRC Development Grant

Category 1

APP1093539

$700,000

Novel prostate cancer target for diagnosis, imaging, detection of recurrence and response to therapy 

Nelson CC, Russell PJ, Walsh BJ, Campbell D.

2014-2017

PCFA Movember Revolutionary Team Award

$4,250,000

Adaptive response to androgen targeted therapies: A strategic offensive on resistance

Nelson CC, et al. (AIs, include PJ Russell).

2015-2016

World Cancer Research (Former AICR), 103624 pounds

~$168,907

A humanized in vivo model to test novel therapeutic strategies against prostate cancer bone metastasis.

Hutmacher D, Denham J, Russell PJ, Williams ED, Levesque J-P, Holzapfel BA. 

2015

ARC – Linkages, Infrastructure and Equipment Fund (LIEF)

Category 1

LEIF 50100067

$390,000

The Vevo 2100 Micro-ultrasound plus LAZR Photoacoustic Imaging Platform 

Russell PJ, Gobe G, Herington A, Langton C, Thurecht K, Brereton I, Frazer I, Fielding A, Hutmacher D, Hill M

2015

Australian Cancer Research Foundation (ACRF)

$4 million ($2.5 m obtained)

ACRF  Facility for Molecular Imaging Agents (AFMIAC)

Reutens D, Cooper MA, Smith MT, Boyd A, Richards L, Bartlett PF, Russell PJ, Walker DG, Bhalla R, Barth M, Palmeri C, Thurecht K, Venkatachalam T, Allavena R, Straw R, Tesiram Y, Bunt J, Francois M, Osborne G.

2014-2015

PCFA/Movember Foundation

Movember Global Action Plan Xenograft Project Grant

Williams ED, Russell PJ, Nelson C

2014

TRI Inter-Institutional Collaborative Research Funding Award

$25,000

Diagnosing small renal masses; solving the clinical problem of how best to manage patients with kidney neoplasms that are not life threatening

Gobe G, Wood S, Coward J, Russell PJ, Saunders N, Lott W (AI Hemamali Samaratunga).

2014-2015

Movember Xenograft project Grant

$112,000

Global Action Plan-Xenografts)

Williams ED, Russell PJ, Nelson CC

2014-2015

Gallipoli Medical Research Foundation

$50,000

 Evaluation of PSMA-based positron emission tomography and magnetic resonance imaging for detection of multiple cancer foci in localized prostate cancer patients.

Heathcote P, Thomas P, Wood S, Greenslade S, Lampe G, Shephard B, Nelson CC, Russell PJ

2013-2017

Australian Government Department of Health and Aging

$6,163,000

Australian Prostate Cancer Research Centre – Queensland

Nelson CC, Clements J, Russell PJ, Herington A, Chopin L, Hutmacher D, O’Byrne K, Graves N, Yates P, Williams ED, Richard D, Wood S, Vela I, Heathcote P, Lehman M, Gogna K, McCaffrey E, Greenslade S, Lampe G, Shepherd B.

2013-2014

Movember Global Exosome Biomarker Project Grant

$227,000

 Development of assays for the capture and detection of prostate cancer-derived exosomes and exosomal markers.

Russell PJ, Soekmadji C, Nelson CC, Hovens C.

2013-2016

NHMRC APP1046831

Category 1

$545,362

Imaging for prostate cancer theranostics

Russell PJ, Whittaker A, Thurecht K (AIs, Nelson C, Coswin G, Heston WD, Emberton M.)

2012

PCFA

NDDA0411

$100,000

 

Simultaneous imaging and drug delivery for prostate cancer theranostics

Russell PJ, Whittaker A, Thurecht K, Heston WW.

2012-2015

NHMRC

APP1031228

Category 1

$606,134

Identification of PACE-1 as a novel therapeutic target for the treatment of prostate cancer

Ling, MT, Quinn R, Russell PJ, (AI: Nelson, C)

2011

ARC - LIEF

Category 1

$330,000

Comprehensive Cell Imaging Facility

Clements J, McMillan N, Whitehead JB, Beagley KW, Russell PJ, Nelson CC, Hutmacher DW, Atkinson MK, Dawson PA, Frazer IH, Gonda TJ, Hooper JD, Levesque JP J, McGuckin MA, Munster DJ, Rice AM, Thomas R, Vuckovic S, Waterhouse NJ.

2011-2014

ARC Discovery

Category 1

DP110103890

$436,000

Development and validation of virtual epithelial cancer models using an integrated modelling and experimental three-dimensional approach

Hutmacher D, McElwain DL, Russell PJ, Flegg JA, Loessner D, Clements J, Dalton PD, Byrne HM.

2011-2013

NHMRC

APP1010141

Category 1

$596,306

KLK4 is a master regulator of tumour microenvironment remodelling in prostate cancer and bone metastasis

Clements J, Nelson C, Hutmacher D, Russel PJ.

2010-2011

Queensland Cancer Council 614273

$196,500

The role of KLK4 in prostate cancer progression

Clements JA, Hutmacher DW, Nelson CC,  Russell PJ.

2010

PCFA

$124,798

Targeted nanoparticles for imaging prostate cancer

Russell PJ, Khatri A, Cowin G, Thierry B, Power C.

2010

PCFA


$30,000

Application for a Syngene G:Box Chemi XT unit

Russell PJ, Nelson CC, Lin P, Clements JA, Harris J, Hooper J, Chopin L, Herington A, Stephenson SA.

2009

Cancer Institute, NSW, Research Equipment Grant

$300,000

Aperio Scan Scope Virtual Slide Scanner for collaborative cancer histopathology

Hawkins N, Ward R, Apte M,  Russell PJ, Sewell W.

2008-2009

NHMRC Development

Category 1

APP497290

$160,500

Potential therapeutic roles for a protease inhibitor

Harris J, Clements J,  Russell PJ.

2008-2010

Cancer Australia and PCFA (NHMRC510239)

$587,525.

Preclinical evaluation of novel prostate-targeted nanoparticles for imaging primary and metastatic prostate cancer

Rusell PJ, Amal R, Walsh BJ, Bucci J, de Souza P.

Changed in 2009 to : Russell PJ, Thierry B, Walsh BJ, Bucci J, de Souza P, Khatri A. $584,000

2008

Goldstar Award, UNSW

$40,000

Preclinical evaluation of novel prostate-targeted nanoparticles for imaging primary and metastatic prostate cancer

Rusell PJ, Amal R, Walsh BJ, Bucci J, de Souza P.

Awarded but not taken up as ARC Linkage successful

2008-2010

ARC Linkage Grants

LP0882720

$372,000

Numerical modelling and experimental studies to design and engineer nanoparticulate systems for bioapplications

Amal R, Russell PJ, Walsh BJ, Gooding J.

2008-2010

NHMRC APP510238

Category 1

$432,000

Combined novel tumour-targeted molecular and traditional chemotherapy for treating androgen refractory prostate cancer

Russell PJ.

2008-2010

UNSW Foundation & PCFA

$300,000

Studies of bone metastasis from prostate cancer

Russell PJ, Power C.

2007

Cancer Inst. NSW,

$240,200

Establishment of networking data base and animal support for live animal imaging

Russell PJ, Khachigian L, Crowe PJ, Rae C, Wlash W, Haber M, Lock R, Yang j-lL, Tuch B, Rose M, Price W, Power C.

2007

UNSW equipment grant

$1,100,000

Major Research and Infra-structure equipment: Vevo and intra-vital microscopy

Khachigian L, Chesterman C, Hogg P, Jessup W, Chong B,  Kritharides L,  Gaus K, Haber M, Norris M, Kavallaris M, Lock R, Brown AJ, Gooding J, Russell PJ, Power C, Amal R, Rose M,  Geczy C, Morris M, Waite P, Ashwell K, Hill M, Carrive P,  Stoodley M, Brew B, Tuch B, Kuldip S.

2007

UNSW, Major Research and Infrastructure

$476,000

MicroCT scanner

Russell PJ, Waite P, Geczy C, Rose M, Khachigian L, Tuch B, Walsh W, Stoodley M, Yang J-L, Carrive P, Lovell N, Power C, Amal R.

2007-2009

Cancer Council NSW

$300,000

Secreted phospholipase A2 in prostate cancer

Scott K, Graham G, Dong Q, Russell PJ.

2007-2009

Cancer Council NSW

$299,650

Chemo-sensitising pathways in ovarian cancer

de Fazio A, Harnett P, Russell P, Associate Investigators: Bowtell D, Guminski A, Byth K, Sharma R.

2007-2009

ARC - LIEF

LP0774951

$75,000

Identification of novel biomarkers in tears for prostate cancer diagnosis and prognosis

Li Y, Willcox MD, Cozzi PJ, Russell PJ, Walsh BJ, Zhao Z.

2007-2009

Sydney Foundation of Medical Research

$225,000

Studies of bony metastases

Russell PJ, Power C

2007-2009

UNSW Faculty of Medicine Strategic Initiatives Grant

$300,000

Establishment of Biomedical Nanotechnology Centre

Kavallaris M, Davis T, Khachigian LM, Norris M, Tuch B, Russell P, Cunningham A, Bulmus V.

2006

MSW Cancer Institute: Equipment grant

$300,000

Imaging system for live small animals (Xenogen IVIS 100 System)

Russell PJ, Crowe PJ, Haber M, Khachigian L, Lock R, Ormandy C, Rose M, Bucci J, Yang J-L, Power C, Khatri A, Kavallaris M, Rawlinson W.

2006-2007

Novartis

$130,000

Inhibition of bony metastases by therapeutic agents from Novartis (alone and in combination) using prostate cancer RM-1(BM)GFP metastasis model in immunocompetent mice

Power C, Russell PJ

2006-2008

NSW Cancer Council

$375,000

The role of the TGF-b superfamily cytokine MIC-1 in the biology of cancer

Breit S, Russell PJ

2005

Prince of Wales Clinical School Research Enhancement Grant

$13,000

The significance of mutations in the FGFR3 gene to bladder cancer progression.

Jackson P, Russell PJ, Hung T-T, Roscioli T.

2005

Prince Henry Centenary Foundation, & Children’s Hospital

$500,000

Purchase of confocal microscope

Cunningham A, Kavallaris M, Russell PJ

2005

Prince of Wales Clinical School Research Enhancement Grant

$13,000

Relationship of EGFR receptor mutation and gene variation in its signalling pathways to the synergistic effect of interferon-alpha plus erlotinib in treatment of human colon cancer cell lines.

Goldstein D, Yang J-L, Russell PJ

2005-2009

NSW Cancer Institute: Translational grant

$3,750,000

Identification and validation of molecular markers of prognosis and therapeutic responsiveness in prostate cancer

Clarke S, Henshall S, Russell PJ, Horvath L, Sutherland R, Kench J, Lee C-Soon, Molloy PL, Grygiel J, Stricker P, Boyer M.

2005

NSW Cancer Institute: Research Infrastructure grant

Infrastructure support for an established cancer genetics/genomics facility.

Hayes V, Ormandy C, Breit S, Butt A, Clark S, Daly R, Grygiel J, Henshall S, Horvath L, Kaplan W, Kench J, Kohonen-Corish M, Musgrove E, O’Brien P, Russell PJ, Sutherland R, Ward RL.

2005-2006

NSW Cancer Institute, Research Infrastructure grant

$214,625

SESAHS Consortium for rational therapeutics

Ward R, Links M, Goldstein D, Russell PJ

2005

Rebecca Cooper Foundation

$16,000

Purchase of a tissue slicer

Katri A, Russell PJ

2004-2006

Department of Veterans’ Affairs Australia

$490,500

Oncogenic action and therapeutic potential of PLA2 in prostate cancer.

Dong Q, Scott K, Graham G, Russell PJ

2005

UNSW Faculty of Medicine Enhancement Grant

$12,000

To purchase real time PCR.

Russell PJ, Erlich J

2004-2008

NHMRC Enabling Grant

$2,100,000

Prostate Cancer Tissue Banking.

Clements JA, Risbridger, V Marshall, D Roder, J Stahl, F Gardiner, D Nicol, M Frydenberg, J Pederson, P Stricker (PJ Russell AI)

2004-2007

US Army Defense  Department, USA

W81XWH-1-004

New Investigator Award

$300,000

Control of micrometastatic prostate cancer using multiple alpha targeted therapy

Li Y, Cozzi PJ, Rizvi SMA, Diwan A, Allen BJ, Russell PJ

2004

Prince of Wales Hospital Oncology Institute Grant

$25,000

Studies of gene array of p53-expressing human prostate cancer cell lines

Blair J, Russell PJ

2004

Prince of Wales Hospital Oncology Institute Grant

$42,000

Studies of chemotherapy and radiotherapy of prostate cancer

Zhang AL, Milross C, Russell PJ

2004

Prince of Wales Hospital Oncology Institute Grant

$20,000

 Top up for gene therapy work

Russell PJ, Khatri A.

2004

Cure Cancer Foundation of Australia

$48,028 awarded but not taken up as Dr Zhao moved.

Purification, identification and functional studies of proteases expressed in prostate cancer cell lines – a functional proteomic study

Zhao J, Russell PJ

2004

Faculty of Medicine, Enhancement grant

UNS $15,000

To purchase fluorescence microsopy imaging equipment

Russell PJ, Erhlich J.

2004

Clive and Vera Ramaciotti

$29,878

Microscopy equipment

Erlich J, Russell PJ

2004

NHMRC equipment grant

$60,000

Purchase of fluorescence microscopy imaging equipment

Russell PJ, Erlich J

2003

Cure Cancer Foundation

$60,000

Purchase of a faxitron

Broan JM, Russell PJ

2003-2005

National Institute of Health and National Institute of Diabetes and Digestive and Kidney Diseases Bethesda

DK067681-01

US $216,000

(~A$342,857)

The role of IL18 in the spread of prostate cancer to the bone

Russell PJ, Martiniello-Wilks R, Zhang A.

2003-2005

Department of Defense, US Army, Alternative Funding

DAMD17-02-1-0107

US$522,000 (~A$900,000)

Formulated delivery of enzyme/pro-drug and cytokine gene therapy to promote immune reduction of treated and remote tumors in mouse models of prostate cancer.

Russell PJ, Both GW, Molloy PL and others from CSIRO

2002-2004

Department of Defense, US Army, New Idea Award

DAMD17-02-1-0108

US$456,000

(~A708,592)

Studies of the role of p53 mutations in metastases of prostate cancer to bone.

Russell PJ, Brown JM

2004

Sydney Foundation for Medical Research

$151,000

Studies of prostate cancer

Russell PJ

2002-2003

Sydney Foundation for Medical Research

$176,000

Studies of proteases in prostate cancer

Russell PJ, Zhao Z

2001

Australian Kidney Foundation, Equipment grant

$13,224

Equipment grant

Russell PJ

2001

Clive and Vera Ramaciotti Foundation

$15,831 (equipment)

Identification of proteases associated with prostate cancer invasion and progression

Daja M, Russell PJ

1999-2003

FH Faulding support for CSIRO, SESAHS

And AusIndustry Start Plus, Funds for ORC, POWH: $1,220,380

Studies of gene therapy

Russell PJ and team

2000-2001

Sydney Foundation for Medical Research

$248,424

Studies of proteases produced by prostate cancer cells, (includes equipment)

Russell PJ, Daja M

1998-2001

AusIndustry  grant,  for CSIRO, CSL and SESAHS

$1,000,000

Lytic peptides for cancer therapy

CSL, CSIRO, Russell PJ teams

1999

Australasian Urological Foundation

$20,000

Cytodine methylation of regulatory sequences near glutaehione-S transferase gene in the peripheral blood of patients with prostate cancer

Russell PJ, Patel M

1999

Leo and Jenny Leukaemia and Cancer Foundation

$49,489

The role of KAI-1 in invasive bladder cancer.

Jackson P, Russell PJ

1999-2001

NHMRC APP990152

$315,000

Category 1

Therapy for prostate cancer using the prostate specific membrane antigen for targeting

Russell PJ, Molloy PL, Both GW, Jackson P

1998-1999

NSW Cancer Council

$150,000

Category 1

Gene therapy for androgen-independent prostate cancer: Preclinical Studies

Russell PJ, Molloy PL, Both GW

1997-1999

Sydney Foundation for Medical Research

$357,270

The relationship between protease activity and onset and progression.

Russell PJ, Whittaker R.

1996

Leo and Jenny Leukaemia and Cancer Foundation

$5000

The role of KAI-1 as an inhibitor of metastasis in human prostate cancer

Russell PJ, Glover H

1996-1997

Workcover NSW

~$150,000

Validation of a monoclonal antibody test for the early detection of bladder cancer

Russell PJ1 Kingsley E, Yu Y

1996-1998

NSW Cancer Council

$156,000

Methylation of tumour suppressor and tumor related genes in prostate cancer.

Clark S, Molloy PL, Russell PJ

1995-1997

NHMRC

Category 1

$294,000

A predictive assay for radiotherapy response in bladder cancer

Russell PJ, Braithwaite AW

1995-1997

NHMRC

Category 1

$311,322

Prostate cell specific expression of a toxin gene delivered by recombinant adenovirus vectors

Russell PJ, Molloy PL, Both GW.

1995-1997

NSW Cancer Council

Category 1

$175,500

Cellular mechanisms involved in the development of androgen-independence and metastases of prostate cancer

Russell PJ, Brown J

1994-1995

AINSE

$6,000

Low dose irradiation of human bladder tumours

Russell PJ

1994

Leo and Jenny Cancer and Leuaemia Foundation of Australia

$40,784

Improved targeting of platinum anticancer drugs in breast and genitourinary tumours

Russell PJ, Hambley T, McKeage M.

1993

Clive and Vera Ramaciotti Foundation

$15,000

Monoclonal antibodies for the treatment of bladder cancer

Russell PJ

1992

Prince Henry Hospital Centenary Research Fund

$25,000

Autocrine growth factor interactions in human bladder cancer

Russell PJ, Brown JL, Nash AR.

1992

Department of Health

$35,000

Care and maintenance of a nude mouse facility

Russell PJ, Vincent PC.

1991-1994

AMRAD

$900,000

Therapeutic studies of human bladder cancer using monoclonal antibodies

Russell PJ, Garsia R, Person B, Pearce N, Raghavan D.

1991

University of Sydney Cancer Research Fund

$28,000

Nude mouse consortium: Maintenance of nude mice for use in cancer research

Russell PJ

1991

-1992

AMRAD

$83,000

Use of monoclonal antibodies for the diagnosis of human bladder cancer

 Russell PJ, Walker KZ, Garsia R, Raghavan D

1991-1992

Worksafe Australia

$90,000

Screening of voided urine for occupational bladder cancer

Garsia R, Russell PJ, Kenyon R, Pearson B.

1991

Royal Prnce Alfred Hospital Medical Fund

$22,000

Cellular and Molecular studies of human bladder and prostate cancer.

Russell PJ, Raghavan D.

1991

Leo and Jenny Leukaemia & Cancer Foundation of Australia

$46,535

Analysis of expression and mutations of p53 and fms genes in urine cells of cancer patients.

Russell PJ, Grimmond S.

1991-1993

NHMRC

Category 1

$139,783

Significance of abnormal expression or mutation of genes in bladder cancer

Russell PJ, Rozinova E, Grimmond S.

1990-1991

NHMRC

Category 1

$82,196

Experimental studies of heterogeneity of response to chemotherapy in bladder cancer

Raghavan D, Bell D, Russell PJ, Foo T.

1990

Australian Kidney Foundation (equipment)

$5,000

Development of nude rat xenograft models for studies of intravesical therapy of human bladder cancer using radiolabelled monoclonal antibodies.

Russell PJ

1990

Leo and Jenny Leukaemia & Cancer Foundation of Australia

$15,000

(equipment)

Predicting response of bladder cancer to anti-cancer drugs

Russell PJ, Raghavan D.

1990

University of Sydney Cancer Research Fund

$30,000

Diagnosis and therapy of human bladder cancer monoclonal antibodies

Walker KZ, Russell PJ

1990

University of Sydney Cancer Research Fund

$26,000

Maintenance of nude mice for use in cancer research

Russell PJ, Raghavan D, Basten A, Mountford C.

1989

University of Sydney Cancer Research Fund

$15,000

Maintenance of nude mice for cancer research

Nude mouse consortium (convenor PJ Russell).

1988

University of Sydney Cancer Research Fund

$23,000

Diagnosis and management of human bladder carcinomas using murine monoclonal antibodies

Walker KZ, Russell PJ

1988

Leo and Jenny Leukaemia & Cancer Foundation of Australia

$22,000

Salary for animal house attendant

Nude mouse consortium (convenor PJ Russell).

1988

Leo and Jenny Leukaemia & Cancer Foundation of Australia

$29,546

(equipment)

Development of metastasis and invasion of human solid tumours

Russell PJ, Grant A

1988-1990

NHMRC

Category 1

$212,796

Studies of gene expression, rearrangement and mutation in urogenital cancers.

Russell PJ, Raghavan D

1986

NSW State Cancer Council

Category 1

$12,424

Protein chemistry of phenotypic variants of prostate cancer

Raghavan D, Russell PJ

1986

NSW State Cancer Council

Category 1

$25,000

 

Small cell undifferentiated carcinoma of the prostate: a model of tumour heterogeneity and studies of polypeptide hormone production.

Raghavan D, Russell P, Russell PJ

1986-1987

NHMRC

Category 1

$114,469

Heterogeneity and differentiation of cancers of the genitourinary tract

Raghavan D, Russell PJ, Vincent PC.

 

Prof Russell has procured more than $36 million in grants, has published more than 200 papers in international journals (H factor 53), and has co-authored six patents.

Research interests

prostate cancer, nanoparticles for imaging and delivery of chemotherapy, gene therapy for late stage prostate cancer, exosomes (small vesicles secreted by cancer cells), origin of cancer cells, identifying biomarkers from protein, miRNA, RNA, DNA or lipid content, animal models of prostate cancer, targeted gene therapy,chemotherapy, castrate resistant prostate cancer, and bony metastasis

Top publications

Of 220 papers, 1 book , editor of 1 book, 19 book chapters...

  • Russell PJ, Hicks JD, Burnet FM.  Cyclophosphamide treatment of kidney disease in (NZB x NZW)F1 mice.  Lancet, 1966; June 11, 287(7450):1279‑84 (Leading article). PMID: 4160875 (121 citations, Google Scholar). This paper describes the first use of cyclophosphamide for potentially treating systemic lupus erythematosus (SlE) in an animal model of disease. Cyclophosphamide is still used clinically to treat cases of SLE that are refractory to steroid therapy.
  • Russell PJ, Raghavan D, Gregory P, Philips J, Wills EJ, Jelbart M, Wass J, Zbroja R, Vincent PC.  Bladder cancer xenografts: a model of tumor cell heterogeneity.  Cancer Res, 1986; 46(4 Pt2):2035‑40. PMID: 2418959. This paper describes the establishment of a series of patient derived xenografts of human bladder cancer, shows that these are extremely heterogeneous with respect to flow cytometry, and histology, and indicates for the first time effective treatment using carboplatin, which has subsequently been adopted into the clinic.
  • Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP.  Biology and management of bladder cancer: advances and innovations.  N Eng J Med, 1990; 322(16):1129-38 Reply: N Eng J Med, 1991; 324:126. PMID: 2181313. This classic paper provided expert information about management and biology of bladder cancer.
  •  Khatri A, Husaini Y,  Ow K, Chapman J, Russell PJ. Cytosine Deaminase-Uracil Phosphoribosyl Transferase and Interleukin-12 and -18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res, 2009;15(7):2323-2234.  PMID19318483. This paper shows that gene therapy and immunotherapy are synergistic against  prostate cancer.
  •  Pearce A, Simpson JD, Fletcher NL, Houston ZH, Fuchs, Whittaker AK, Russell PJ, Thurecht KJ. Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic.  Biomaterials, 2017;141:330-339. PMID:8711780 https://doi.org/10.1016/j.biomaterials.2017.07.004. This work uses a theranostic targeted to prostate cancer using a small molecule that binds to prostate specific membrane antigen. Both imaging and tumour regression were obtained.
More publications are available on PubMed

Team

  • Brian Tse Postdoctoral Research Fellow, APCRC-Q

Collaborators

  • Dr Warick D Heston, Lerner Institute, Cleveland Clinic, USA
  • Prof Andrew Whittaker and Dr Kristofer Thurecht, Australian Institute of Biotechnology and Nanotechnology, University of Queensland
  • Dr Benjamin Thierry, Ian Wark Institute, University of South Australia
  • Dr Jonathan Harris, Institute of Health and Biomedical Innovation, QUT
  • Dr David MacFarlane, FRACP, Director, Queensland Positron Emission Tomography Service, Deputy Director, Nuclear Medicine, Royal Brisbane & Women's Hospital,  Queensland
  • Prof Andrew Boyd and Dr Jennifer Ellacott, Queensland Institute of Medical Research
  • Dr Michelle Hill, Diamantina Institute, University of Queensland

Professional memberships and associations

Membership of Professional Societies

Current Urological Society of Australasia:  Associate Member
Current Gene Therapy group now Honorary Life member, Australian Society for Gene Therapy
Current Associate member of American Association for Cancer Research
1991-2010 Member of Clinical Oncology Society of Australia
1993-2000 Founding Member, Genitourinary Cancer Urological Group
1998-1999 Vice-Chairman, Genitourinary Cancer Urological Group
1966-1995 Member of Australian Society for Immunology
1998 Executive Member, Australian Society for Gene Therapy
2007-2010 Secretary and Director, ANZUP Australian and New Zealand Prostate and Urological Cancer Clinical Trials Group Ltd

1995-2003

Founding member, and Director, Prostate Cancer Foundation of Australia

1995-2000

Peer review Committee, Prostate Cancer Foundation of Australia

2007 on

Member, Scientific Advisory Committee, ANZUP

2007 on

Member, Scientific Advisory Committee, ANZUP Prostate Cancer

Leadership in Professional Societies and Associations

1977-1978 Qualifications Committee of the Austrlaian Society of Microbiology
1979 Education Officer of the Australian society of Microbiology for ACT
1991 Member of Research Committee of COSA
1993 Founding member of Genitourinary Oncology Group GUOG
1995-1996 Secretary, GUOG
1998-1999 Vice-Chairman, GUOG
1998 Executive, Gene Therapy Group, NSW
1998-2000 Board Member, Prostate Cancer Research Foundation
2002- Member of Bioresource Committee, APCC
2004- Executive Member, APCC
2002-2004 Member of Board of Management of Biological Resources Centre (BRC), UNSW
2004-2006 Member of Advisory Committee of Biological Resources (BRAAG), UNSW
2004- Member of IP Committee, St Vincents Hospital, Sydney
2003-2006 Member of Cancer Care Committee, South Eastern Sydney Area Health Service
2005-2006 Executive member, Scientific steering Committee, Prostate Cancer Foundation of Australia
2006- Executive Member, Urological Oncology Program, NSW Cancer Institute
2007-2010 Secretary, Director, Australian Prostate and Urological Cancer Clinical Trials Group, ANZUP,